Search Results - trail

4 Results

Sort By:

Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)

Abstract: The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment. Therapeutics...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Yang Feng

Keywords(s): ANTIBODY, death receptor, Dr4, Mab, TRAIL

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Analogues of Withanolide E Sensitize Cancer Cells Toward Apoptosis

Abstract: The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) protein has been a target of interest in cancer therapy because it plays a large role in inducing cell apoptosis in cancer cells but not in normal cells. Although TRAIL has been reported to successfully target certain tumor cells which are resistant to traditional chemotherapy...

Published: 5/22/2024 | Inventor(s): Thomas Sayers, Alan Brooks, Curtis Henrich, Poonam Tewary, James McMahon, Leslie Gunatilaka, Yaming Xu, Kithsiri Wijeratne

Keywords(s): APOPTOSIS, Immunotherapy, TLR3 ligands, TRAIL, withanolide

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Use of Cucurbitacins and Withanolides for the Treatment of Cancer

Abstract: Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL "death receptors". These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death...

Published: 5/22/2024 | Inventor(s): Thomas Sayers, Kirk Gustafson, Karen Erickson, Alan Brooks, Curtis Henrich, Nancy Booth

Keywords(s): cucurbitacin, Immunotherapy, mapatumamab, TRAIL, withanolide

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer

This technology includes the use of a beclin 1 inhibitor, 17-hydroxy Wortmannin, for the treatment of TRAIL-resistant colon cancer. TRAIL (TNF-related apoptosis-inducing ligand) binds to death receptors (DR4/DR5) and activates apoptosis in cancer cells. Multiple clinical trials have focused on promoting TRAIL-induced death but have had a lack of efficacy...

Published: 7/25/2024 | Inventor(s): Sheng Dai, Wei Zheng

Keywords(s): 1, 17-hydroxy, Autophagy, Beclin, CANCER, Cells, COLON, Increased, Inhibitions, Overcomes, Resistance, TRAIL, VCXXXX, WIXXXX, WKXXXX, Wortmannin, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Research Materials, Application > Therapeutics